Needham Keeps Their Hold Rating on Omeros (OMER)

Needham analyst Serge Belanger maintained a Hold rating on Omeros (OMERResearch Report) today. The company’s shares closed last Monday at $14.31.

According to, Belanger is a 1-star analyst with an average return of -1.4% and a 43.0% success rate. Belanger covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals, Collegium Pharmaceutical, and Zynerba Pharmaceuticals.

Omeros has an analyst consensus of Moderate Buy, with a price target consensus of $28.33, representing an 111.6% upside. In a report issued on October 29, Wedbush also reiterated a Hold rating on the stock with a $18.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.92 and a one-year low of $10.30. Currently, Omeros has an average volume of 404.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.